ConductScience.org, home

Paper25534129

A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501.

Nogami N and 21 others. Lung Cancer, 2015. Cited by 29 papers, by iCite.

Cite this record

ConductScience Library. A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501. Papers, record 25534129. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25534129

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501.
PubMed
Journal
Lung Cancer
PubMed
Year
2015
PubMed
Publication types
Clinical Trial, Phase II, Journal Article
PubMed
Citations, by iCite
29
iCite
Relative citation ratio, by iCite
0.85
iCite
Revised in PubMed
2022-04-09
PubMed

Authors22

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Nogami NNaoyuki
2Takigawa NNagio
3Hotta KKatsuyuki
4Segawa YYoshihiko
5Kato YYuka
6Kozuki TToshiyuki
7Oze IIsao
8Kishino DDaizo
9Aoe KKeisuke
10Ueoka HHiroshi
11Kuyama SShoichi
12Harita SShingo
13Okada TToshiaki
14Hosokawa SShinobu
15Inoue KKoji
16Gemba KKenichi
17Shibayama TTakuo
18Tabata MMasahiro
19Takemoto MMitsuhiro
20Kanazawa SSusumu

Source PubMed

See all 22 authorsDownload CSV of authors

Topics22

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Carcinoma, Non-Small-Cell LungMajor topic
Lung NeoplasmsMajor topic
RadiotherapyMajor topic
Adult
Aged
Chemoradiotherapy
Cisplatin
Disease Progression
Drug Combinations
Female
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
Neoplasm Staging
Oxonic Acid
Radiotherapy Dosage
Retreatment
Survival Analysis
Tegafur
Treatment Outcome

Source PubMed

Download CSV of topics

Cited by17

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 29 citations.

PMIDTitleJournalYearIn PapersSource
41099317Acute Radiation Esophagitis After Chemoradiotherapy Demonstrating "Tube-Like" FDG Uptake on PET-CT: Case Report and Literature Review.Cancer Rep (Hoboken)2025https://conductscience.org/library/papers/41099317PubMed
40837011A phase I study of S-1 and cisplatin with concurrent hypofractionated carbon-ion radiotherapy for patients with stage III non-small cell lung cancer.Front Oncol2025https://conductscience.org/library/papers/40837011PubMed
39910007Five-year outcomes with gefitinib induction and chemoradiotherapy in EGFR-mutant stage III non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study.Int J Clin Oncol2025https://conductscience.org/library/papers/39910007PubMed
37781162Comparison of post-chemoradiotherapy pneumonitis between Asian and non-Asian patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis.EClinicalMedicine2023https://conductscience.org/library/papers/37781162PubMed
36570411
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis.
Ther Adv Med Oncol2022https://conductscience.org/library/papers/36570411PubMed
35923924
Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study).
Ther Adv Med Oncol2022https://conductscience.org/library/papers/35923924PubMed
35869676Phase II study of S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Results of the LOGIK1605/JART-1501 study.Thorac Cancer2022https://conductscience.org/library/papers/35869676PubMed
35000608Concurrent chemoradiotherapy with cisplatin + S-1 versus cisplatin + other third-generation agents for locally advanced non-small-cell lung cancer: a meta-analysis of individual participant data.BMC Pulm Med2022https://conductscience.org/library/papers/35000608PubMed
33717228A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study).Ther Adv Med Oncol2021https://conductscience.org/library/papers/33717228PubMed
33319495Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer.Cancer Med2021https://conductscience.org/library/papers/33319495PubMed
32675194Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibitors in treating pancreatic cancer.J Immunother Cancer2020https://conductscience.org/library/papers/32675194PubMed
32099495Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non-Small Cell Lung Cancer: Emerging Mechanisms and Perspectives.Lung Cancer (Auckl)2019https://conductscience.org/library/papers/32099495PubMed
32020735S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Study protocol of LOGIK1605/JART-1501.Thorac Cancer2020https://conductscience.org/library/papers/32020735PubMed
30673966Concurrent chemoradiotherapy using cisplatin and S-1, followed by surgery for stage II/IIIA non-small cell lung cancer.Gen Thorac Cardiovasc Surg2019https://conductscience.org/library/papers/30673966PubMed
30655791ROS1-rearranged high-PD-L1-expressing lung adenocarcinoma manifesting as mediastinal tumor: A case report.Oncol Lett2019https://conductscience.org/library/papers/30655791PubMed
30206369A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L.Br J Cancer2018https://conductscience.org/library/papers/30206369PubMed
29642202S-1-based concurrent chemoradiotherapy in the treatment of locally advanced non-small cell lung cancer: A systematic review and meta-analysis protocol.Medicine (Baltimore)2018https://conductscience.org/library/papers/29642202PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/25534129

GET https://conductscience.org/api/papers/v1/25534129/authors?page=2